A U.S. appeals court ruled that companies cannot import Gilead Sciences' medications from overseas, targeting alternative funding programs that source these drugs abroad.
Impact: The decision could limit Gilead's market reach and pressure its pricing, potentially weighing on its stock.
Not investment advice